In the past few years, the pharmaceutical industry has been very active in the field of anti-cancer technology, with the total transaction involving six companies exceeding 500 million US dollars. In addition to the huge potential of capital inflow, the measures taken by the US Food and Drug Administration (FDA) have also promoted the development of this field. In order to meet the growing medical needs, FDA gives priority to the evaluation of CAR-T cell therapy. Many of these therapies are certified as "rare disease therapy" and "breakthrough therapy". The rapid management audit mechanism in turn promotes the faster development of technology and the faster inflow of funds. On October 20 14, 165438+ 10, the FDA awarded Juno the certificate of "JCAR0 15" for treating rare diseases; The "KTE-C 19" developed by Kite Company for relieving non-Hodgkin's lymphoma has also been certified by FDA and European Drug Administration. The "CTL0 19" (used to treat acute lymphoblastic leukemia) developed by the University of Pennsylvania and Novartis was also certified as "breakthrough therapy" in July last year.
With the deepening of research, the results of clinical trials have also brought hope to people. Scientists participating in this research competition are encouraged by these experimental results, and many people think that CAR-T cell therapy is the future of cancer treatment.